Low-dose naltrexone (LDN) is generating growing interest as a potential therapy for conditions such as chronic pain and immune-related disorders. This episode offers a foundational overview of what LDN is, how it’s thought to work, where current evidence stands, and how pharmacists may encounter it in practice. Learn what pharmacists need to know to confidently approach patient questions about LDN and how it fits into current conversations in pharmacy and patient care.

HOST
Joshua Davis Kinsey, PharmD
VP, Education
CEimpact

GUEST
Michelle Moser, RPh
Retired Compounding Pharmacist

Joshua Davis Kinsey has no relevant financial relationships to disclose.

Michelle Moser was a volunteer board member for LDN Research Trust (ended June 2025), a board member for Alliance for Pharmacy Compounding (ended September 2024), and an employee of Revelation Pharma (ended June 2024). All relevant financial relationships have been mitigated.   


CPE REDEMPTION
This course is accredited for continuing pharmacy education! Click the link below that applies to you to take the exam and evaluation:

• If you are already enrolled in this course, click here to redeem your credit. 
• To purchase this episode and claim your CPE credit, click here. 

CPE INFORMATION
Learning Objectives
Upon successful completion of this knowledge-based activity, participants should be able to:
1. Define low-dose naltrexone (LDN) and describe how it differs from traditional naltrexone dosing.   
2. Identify proposed mechanisms of action and areas of emerging interest related to LDN use in practice.

0.05 CEU/0.5 Hr
UAN: 0107-0000-25-275-H01-P
Initial release date: 8/25/2025
Expiration date: 8/25/2026
Additional CPE details can be found here.

Follow CEimpact on Social Media:
LinkedIn
Instagram